Amphastar Pharmaceuticals (NASDAQ:AMPH) Rating Reiterated by Needham & Company LLC

Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “hold” rating reiterated by stock analysts at Needham & Company LLC in a research note issued on Thursday, Benzinga reports.

A number of other analysts have also recently weighed in on the stock. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. Piper Sandler reiterated an “overweight” rating and set a $71.00 target price on shares of Amphastar Pharmaceuticals in a research note on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $63.00.

Amphastar Pharmaceuticals Stock Performance

AMPH traded down $1.21 on Thursday, reaching $42.85. The company had a trading volume of 365,605 shares, compared to its average volume of 419,695. The company has a quick ratio of 1.72, a current ratio of 2.18 and a debt-to-equity ratio of 0.88. Amphastar Pharmaceuticals has a 1 year low of $36.56 and a 1 year high of $65.92. The stock has a market capitalization of $2.10 billion, a PE ratio of 14.83, a P/E/G ratio of 0.75 and a beta of 0.79. The stock has a 50-day moving average price of $40.36 and a 200-day moving average price of $44.10.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.20. The firm had revenue of $171.84 million during the quarter, compared to analysts’ expectations of $171.13 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. As a group, research analysts forecast that Amphastar Pharmaceuticals will post 3.59 EPS for the current fiscal year.

Insider Transactions at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 10,282 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $4,162,175.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,282 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at $4,162,175.69. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $41.40, for a total transaction of $124,200.00. Following the transaction, the director now directly owns 78,409 shares in the company, valued at $3,246,132.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,378 shares of company stock worth $747,482. Company insiders own 27.10% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several hedge funds have recently bought and sold shares of AMPH. Principal Securities Inc. acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at about $34,000. YHB Investment Advisors Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at approximately $27,000. Quadrant Capital Group LLC increased its stake in shares of Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after purchasing an additional 223 shares in the last quarter. Innealta Capital LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter worth approximately $55,000. Finally, Blue Trust Inc. raised its position in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.